Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02).
This multicenter phase II trial evaluated trastuzumab emtansine (T-DM1) in 36 patients with HER2-positive metastatic bre...